Fig. 1 | British Journal of Cancer

Fig. 1

From: Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

Fig. 1

TTPr distribution in patients enrolled in successive Phase1/1b trials. TTPr is reported using Kaplan–Meier estimate to account for possibly censored observations. This estimate is hypothesised to correspond to a reference population with “overall no treatment line effect”. A: Distribution of TTPr in the overall population. The median TTPr in this population is highlighted with dotted lines. B: Distribution of TTPr according to the participation to a trial based on molecular orientation. Data is represented for patients included in a molecularly-oriented trial as first trial only, second trial only, and in none or in both trials

Back to article page